Cambridge Healthtech Institute (see archive)

• Proteins: Selection, Synthesis, and Purification Strategies for Optimizing Drug Discovery

• How Will the Diagnostic Company Business Model Evolve to Incorporate Pharmacogenomics
• New Study Addresses Key Issues and Requirements Shaping the Adoption of Pharmacogenomics Testing

• Successful Pharmacogenomics Business Models

• Molecular Diagnostics: Technological Advances Fueling Market Expansion

LeadDiscovery DailyUpdates - subscribe!

LeadDiscovery listing of important papers - see archive and below:

• Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care

• Emerging treatments for inflammatory bowel disease

• Progress in the treatment of peripheral arterial disease (PAD)

• Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

• Incomplete control of HbA1c levels is the major drawback to current non-insulin antidiabetics

• SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

• Emerging treatments for inflammatory bowel disease

• Incomplete control of HbA1c levels is the major drawback to current non-insulin antidiabetics

• SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

• An introduction to the key CNS Disorders

• COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact

• HIV infection - changes in epidemiology driving R&D development and increased market value

• Therapeutic activity of Bayer's BAY 43-9006 in renal cell carcinoma

• New molecular target identified for the prevention of Alzheimer's disease

LeadDiscovery publishes every 2 weeks R&D highlights focuses on:

• Targeted Cancer Therapy: 

• Target "Lifestyle"

• Airway disease: 

• Oncology:  

• CardioVascular disease:

• Focus on Pain

• Metabolic Diseases: 

• Immunology & Inflammatory disease: 

• Functional Genomics: 

• Infectious disease:  

• Assay Technology: 

• CNS Disease: 

• Angiogenesis: 

• Metastasis: 

• Cell Death: 

• Licensing Opportunities/Patent Update:

• Industrial development: 

Free titles include:

• HMP-12 an adrenoceptor antagonist for the treatment of male and female sexual dysfunction

• Cytokine involvement in the symptoms of the common cold: Opportunities for blockbuster therapies

• Novel strategies for developing pro-apoptotic ceramidase inhibitors

• Antibodies to PlGF as anti-angiogenesis therapies for cancer, proliferative retinopathy and acute inflammatory diseases

• Microplasmin, a novel neuroprotective thrombolytic agent for the treatment of ischemic stroke

• TGX-mAbFVIII-1, a type II monoclonal antibody to Factor VIII for anticoagulation

• SY161, a cost-effective treatment of acute myocardial infarction